Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
BMJ Case Rep ; 16(1)2023 Jan 30.
Artículo en Inglés | MEDLINE | ID: covidwho-2223612

RESUMEN

We present the case of a teenaged boy who attended our Ear, Nose and Throat Emergency clinic with a left-sided lower motor neuron (LMN) facial nerve paralysis associated with sensory loss in the distribution of the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve. This happened 3 days following a first dose of the Pfizer-BioNTech BNT162b2 vaccine. He had a House-Brackmann grade V facial palsy, with marked inability to close the left eye. He was treated with a 10-day course of oral steroids and referred to ophthalmology for eye care. He had an MRI scan of the head, which revealed no space occupying lesions or other abnormalities. Over the 6-week period of follow-up, the patient's V1 and V2 sensation gradually resolved, along with improvement of his LMN facial nerve palsy to House-Brackmann grade 3. Despite the potential temporal relationship, it is not possible to establish a causal relationship between the patient's symptoms and the Pfizer-BioNTech BNT162b2 vaccine, thus further research is required.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Parálisis Facial , Enfermedades del Nervio Trigémino , Adolescente , Niño , Humanos , Masculino , Vacuna BNT162 , COVID-19/complicaciones , Vacunas contra la COVID-19/efectos adversos , Parálisis Facial/etiología , Nervio Trigémino , Enfermedades del Nervio Trigémino/complicaciones , Vacunación/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA